Background Clinical prognostic groupings for localised prostate cancers are imprecise, with 30-50% of patients recurring after image-guided radiotherapy or radical prostatectomy. We aimed to test combined genomic and microenvironmental indices in prostate cancer to improve risk stratifi cation and complement clinical prognostic factors.
Introduction
Every year, almost 900 000 men worldwide are diagnosed with prostate cancer, and 250 000 men die annually from the disease. 1 Most cases are localised cancers, which are stratifi ed into low-risk, intermediate-risk and high-risk groups on the basis of their prostate cancer-specifi c mortality. 2 These clinical prognostic groups are based on of treatment. By contrast, patients with intermediate risk (Gleason scores of 7, PSA concentrations of 10-20 ng/mL, or T2b-c) and high risk or locally advanced (Gleason scores ≥8, prostate specifi c antigen concentrations ≥20 ng/mL, or T3/4) prostate cancer often undergo radical prostatectomy or image-guided radiotherapy, or receive intensifi ed regimens adding adjuvant androgen deprivation therapy or novel systemic drugs to prevent progression to metastatic castration-resistant prostate cancer. However, use of treatment intensifi cation for individual patients is imprecise: 30-50% of patients have biochemical relapse despite radical prostatectomy or image-guided radiotherapy. 4, 5 Furthermore, nearly 20% of intermediate-risk patients have biochemical failure within 18 months of primary local therapy (ie, rapid failure). Such failure might be be due to pre-existing occult metastatic disease, because rapid biochemical failure is a surrogate for prostate-cancer-specifi c mortality. 6, 7 The basis of this interpatient clinical heterogeneity has not been clinically resolved. 8, 9 A signature to classify patients as potential responders or non-responders to local therapy would have great clinical use if it was treatment-independent (ie, eff ective both for patients undergoing radical prostatectomy or image-guided radiotherapy) and could be done on initial diagnostic biopsies. Such a signature could triage patients at greatest risk of failure into clinical trials for treatment intensifi cation and justify potential added toxic eff ects. 7, 10 DNA copy number alterations in PTEN, NKX3-1, MYC, and STAR are associated with adverse prognosis, 11, 12 and RNA-based gene signatures might diff erentiate indolent and non-indolent, lethal prostate cancer. [13] [14] [15] TMPRSS2-ERG fusion status does not predict prognosis after radical prostatectomy or image-guided radiotherapy. 16, 17 Importantly, tumour cells exist within a heterogeneous tumour microenvironment with dynamic gradients of hypoxia that have been linked to metastatic potential. 9, 18 Indeed, patients with prostate cancer with hypoxic tumours rapidly fail treatment (eg, within 2 years) after radical prostatectomy or image-guided radiotherapy. 19, 20 Up to now, the interplay of genomic instability and tumour microenvironment in modulation of treatment outcome has been unexplored. We therefore aimed to develop clinically relevant prognostic indices, with use of integrated tumour DNA and microenvironmental indices, to robustly predict patient outcome.
Methods

Study design and patients
Our training (Toronto) cohort for generation of biopsybased signatures consisted of pre-image-guided radiotherapy, clinically-staged patients with prostate cancer, who were classifi ed as low-risk or intermediaterisk on the basis of National Comprehensive Cancer Network guidelines (appendix). 3 To validate our fi ndings, we used copy number alteration profi les from two cohorts of clinically staged (ie, similar to pre-imageguided radiotherapy patients) low-risk to high-risk radical prostatectomy patients (Memorial Sloan Kettering Cancer Center cohort [MSKCC] and Cambridge cohorts; appendix). 8 The radical prostatectomy cohorts were considered both separately and together. We defi ned copy number alteration profi les relative to the hg19 human genome build.
DNA was extracted from pretreatment biopsies that consisted of at least 70% tumour cells as estimated by a pathologist (TvdK), and a custom array was used to detect copy number alterations. 12 Intraglandular measure ments of partial oxygen pressure were taken before radiotherapy with an ultrasound-guided transrectal needle piezoelectrode. 20 We developed four prognostic indices and validated them for prediction of biochemical relapse (appendix). The appendix provides an overview of our approach to develop treatment-independent, integrated prognostic indices. First, we identifi ed unique genomic subtypes with use of unsupervised hierarchical clustering. Second, we used the percentage of a patient's genome harbouring copy number alterations (percent genome alteration) as a surrogate for genomic instability, and assessed this proportion together with tumour hypoxia. Third, we undertook supervised machine learning with a random forest 21 to develop a statistical model, resulting in a DNA signature, which classifi ed patients at risk of biochemical relapse on the basis of their copy-number profi les. We compared the resulting signature with published RNAbased signatures.
Statistical analysis
Our main aim was the development of a set of prognostic measures capable of stratifying patients for risk of biochemical relapse (defi ned as an increase in concentration of prostate-specifi c antigen of at least 2 ng/mL above the post-radiation nadir value for imageguided radiotherapy patients and, for radical prostatectomy patients, as two consecutive concentration values >0·2 ng/mL or triggered salvage radiotherapy 22, 23 ) 5 years after primary treatment. Our secondary aim was the status at 18 months. We assessed prognosis for biochemical relapse by the area under the receiver operator curve (AUC), C-index analysis, and Cox proportional hazard regression models. We modelled indices with univariate and multivariate analyses, with multivariate analyses correcting for Gleason score and pre-treatment concentrations of PSA (and clinical T stage during assessment of high-risk patients; appendix). The appendix shows full C-index analyses for each biomarker. We used two-sided non-parametric tests to compare patient subsets. We applied multiple-testing correction with the Benjamini-Hochberg or Bonferroni method, as indicated. We did all bioinformatic and statistical analyses in the R statistical environment (version 3.0.2).
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and the corresponding author had fi nal responsibility for the decision to submit for publication.
Results
We used information derived from 126 pre-imageguided radiotherapy biopsies (Toronto cohort) and did initial validation with 154 radical prostatectomy specimens (MSKCC cohort). We obtained a secondary independent cohort of 117 radical prostatectomy specimens for further validation of putative biomarkers (Cambridge cohort). Clinical characteristics of the patients are listed in the appendix (pp [11] [12] . We focused on clinically-matched validation cohorts containing low-risk and intermediate-risk patients (n=210) who might need treatment intensifi cation beyond local therapy alone, but also considered all patients with localised disease who might be candidates for intensifi cation or de-intensifi cation (full validation cohort n=271). 5-year biochemical relapse-free survival of the three study cohorts were broadly similar (appendix pp 36-39). Pretreatment PSA was prognostic in imageguided radiotherapy patients, whereas pretreatment Gleason score, T category, and PSA were all prognostic in the full MSKCC and Cambridge cohorts (table 1) .
Our initial analyses showed that Toronto and MSKCC cohorts showed extensive genomic heterogeneity, even for patients who were low-risk or intermediate-risk, or had Gleason scores of 6 or 7 (appendix pp 13, 40-43). The most recurrent copy number alterations in either cohort were 8p amplifi cations and 8q deletions, in addition to deletions of 16q23·2 and 6q15 (harbouring MAF and MAP3K7; table 2), which have been noted in aggressive tumours. 24 We established the frequency of copy number alterations for a set of genes putatively prognostic for adverse outcomes, selected from our previous studies and the literature, in the Toronto image-guided radiotherapy biopsies (appendix p 44). Despite low-risk or intermediate-risk classifi cation, 76 (60%) of 126 patients had copy number alterations in at least two adverse prognosis genes. We noted this variability across the genome, suggesting that genomically defi ned subtypes of prostate cancer might be obtained from biopsies.
Unbiased hierarchical clustering in the Toronto cohort (appendix pp 45-46) showed four localised prostate cancer subtypes with distinct genomic profi les: subtype 1 (characterised by gain of chromosome 7), subtype 2 (deletion of 8p and gain of 8q), subtype 3 (loss of 8p and 16q), and subtype 4 (so-called quiet genomes due to few genomic alterations). Subtypes 2 and 3 share many common genetic alterations (504 genes altered in >25% of patients in both subtypes), but χ² tests showed eight regions that diff ered signifi cantly, including gain of 8q in 
Data are hazard ratio (95% CI) or hazard ratio (95% CI; p-value). 5-year biochemical relapse rate was used in the Cox proportional hazard models except for the Cambridge cohort in which 18-month biochemical relapse rate was used. In a pooled analysis of low-risk and intermediate-risk patients (using the Toronto and MSKCC cohorts; 250 patients), the four genomic subtypes of localised prostate cancer had signifi cantly diff erent prognoses, even after adjustment for clinical variables (fi gure 1, appendix pp [15] [16] [17] [18] [19] [43] [44] [45] [46] [47] [48] [49] . Patients classifi ed as subtype 4 had a signifi cantly better prognosis compared with those with other subtypes (fi gure 1). Biochemical relapse-free survival at 5 years was 58% (95% CI 37-92) for subtype 1, 55% (37-81) for subtype 2, 53% (37-78) for subtype 3, and 89% (84-94) for subtype 4. Subtype 1 seems to be characterised by increased relapse after 3 years rather than increased risk at all times, but larger cohorts are needed to clarify this fi nding. These subtypes are prognostic for biochemical recurrence by 18 months (log-rank p value 0·0024, low-risk to intermediate-risk cohort), which is associated with increased prostate-cancer-specifi c mortality. 6, 7 Indeed, in the Toronto cohort, being subtype 2 was associated with signifi cantly worse overall survival than being in subtype 4 (HR 4·2 (95% CI 1·2-15; Wald p=0·03; appendix p 19).
The excellent prognosis of so-called quiet subtype 4 suggested that genome-wide instability might be prognostic in itself. With the percentage of the genome showing a copy number alteration as a proxy for genomic instability, we noted interpatient variability in percentage of genome alteration ranging from 0-52% in the Toronto cohort, to 0-34% in the MSKCC cohort, and 0-28% in the Cambridge cohort. Percentage of genome alteration was independent of Gleason score, T category, and PSA in all cohorts (fi gures 2A-C). Indeed, individual Gleason score-6 tumours had a higher percentage of genome alteration than did some Gleason score 4 + 3 tumours (fi gure 2A), suggesting that percentage of genome alteration refi nes biological description even in tumours of mainly pattern 4. As expected, based on previous fi ndings, the percentage of genome alteration was increased in patients with prognostic CHD1 deletions (appendix p 50). 25 Percentage of genome alteration was strongly prognostic, independent of clinical covariates, as previously reported. 26 Every 1% increase in percentage of alteration led to a 5-8% decrease in 5-year biochemical relapse-free survival (C-index 0·60-0·72; appendix pp 20-21). To classify the likelihood of clinical failure on the basis of percentage of genome alteration, we set the upper tertile of 7·49% from the Toronto cohort as the lower bound threshold, which effi ciently stratifi ed patients who underwent either image-guided radiotherapy (multivariate analysis HR for biochemical relapse 4·5 [95% CI 2·1-9·8]; Wald p=0·00013) or radical prostatectomy (eg, pooled radical prostatectomy low-risk to intermediate-risk cohort: multivariate analysis HR for biochemical relapse 4·0 [1·6-9·7]; Wald p=0·0024; fi gure 3A-C). These results are threshold-independent (appendix p 51). The HR for the pooled radical prostatectomy full (ie, low, intermediate, and high-risk) cohort at 5 years was 2·7 (95% CI 1·5-4·8; p=0·0024; AUC 0·57 [95% CI 0·52-0·61]). Percentage of genome alteration stratifi es patients at risk of rapid failure consistent with occult metastases, and was increased in Hypoxia is an important aspect of cancer metabolism and in itself can be prognostic in patients with prostate cancer. 19, 20 We used three hypoxia RNA signatures that have been validated in other tumour types to estimate hypoxia within the pooled radical prostatectomy mRNA cohorts (108 MSKCC patients and 110 Cambridge patients; table 3 and fi gure 4A-C; appendix p 22). [27] [28] [29] None of these signatures were univariately prognostic, nor were they related to Gleason score, PSA, T category, or percentage of genome alteration (appendix 56-59). However, when we separated patients into four groups on the basis of high versus low percentage of genome alteration and high versus low hypoxia values, we found that hypoxia increased the prognostic accuracy of the percentage genome alteration for risk of biochemical relapse. Patients with a high percentage of alteration and high hypoxia have the worst prognosis, whereas those with high hypoxia alone (low percentage of alteration) responded well after radical prostatectomy (fi gure 4A-C, appendix pp 23-24, 60-61).
To validate this fi nding, we used the Toronto cohort because the biobanking of frozen biopsies was completed with simultaneous and direct assessment of tumour hypoxia at the same intraprostatic locale. 20 This cohort therefore contained direct measurements of hypoxia denoted by patient-specifi c values for proportion of oxygen measurements less than 20 mm Hg (HP20; appendix p 25). 20 The median HP20 in our cohort was 81% (range 64-93). Although previous fi ndings in a larger cohort have shown that hypoxia was independently prognostic of image-guided-radiotherapy outcome, our results did not show any signifi cant association between median HP20 and increased biochemical-free survival (log-rank p=0·13; appendix p 62). 20 Directly measured HP20 values were not related to the clinical covariates, genomic subtype, percentage of genome alteration, or with any individual copy number alteration, appendix pp 63-65), supporting a unique role in tumour biology of prostate cancer. We again noted that patients with a low percentage of genome alteration and low hypoxia had the best outcome (biochemical relapse-free survival at 5 years was 93%), whereas those with high levels of both measures had the worst (49%; fi gure 4D). Moreover, we recorded a statistically signifi cant interaction between -12] ; Wald p=0·019; appendix pp 26-27) when used as a combined prognostic index. Again, patients whose tumour solely showed hypoxia, but not genome alteration, fared better than expected for patients with hypoxic tumours after image-guided radiotherapy, suggesting that cohorts of patients with high hypoxia and a high percentage of genome alteration could benefi t from treatment intensifi cation. Because specifi c genes (fi gure 1), general genomic instability (fi gures 2, 3), and tumour microenvironment (fi gure 4) all play a part in determination of patient prognosis, we postulated that a supervised machine learning approach would capture the complex and unknown interactions between genes underlying these events. Using a random forest 21 classifi er trained on the Toronto cohort, we developed a biopsy-driven prognostic signature that predicts biochemical failure and could guide clinical decisions before, and independent of, treatment (appendix pp 66-67). The resulting 100-loci (276 genes) DNA signature was validated in two independent cohorts (fi gure 5; appendix 28-30, 68-77). We fi rst verifi ed the signature in the independent lowrisk and intermediate-risk MSKCC cohort, in which it predicted biochemical relapse with an area under the curve of 0·74 (95% CI 0·65-0·83). This signature is more eff ective than clinical variables for prediction of biochemical relapse ( 
Data are hazard ratio (95% CI; p value) or hazard ratio (95% CI). Hazard ratios were not adjusted for clinical variables and the pooled radical prostatectomy cohorts are shown for all three RNA hypoxia signatures. AUC=area under the receiver operator curve. *The Cox proportional hazard model was fi t with four levels (percentage of genome alteration status/hypoxia status: +/+, +/−, −/+, and −/−, whereby +/+ patients had a high percentage of genome alteration and high hypoxia, +/-patients had high a high percentage of genome alteration and low hypoxia, etc), with −/− patients used as the baseline group. Table 3 : Data for patients stratifi ed by hypoxia p=0·021) and was highly prognostic for low-risk patients (AUC 0·97 [95% CI 0·82-1·0]; appendix pp 71-75). Importantly, the signature also identifi ed patients who go on to develop metastasis (AUC 0·78 [95% CI 0·63-0·93]; appendix p 76).
To underpin the potential use of our DNA signature, we noted that the signature had AUC and C-index values that were greater than 97% (970 000/1 000 000) of the empirical null distribution from randomly sampled genesets (appendix p 77). Furthermore, our signature outperformed 23 previously published RNA signatures for prostate cancer biochemical relapse-free survival rates after training of random forests with a cohort of 1299 low-risk to high-risk patients with prostate cancer (including 293 low-risk to intermediaterisk patients) with mRNA microarray data (fi gure 6). Application of these trained forests to the 108 MSKCC patients with information about both mRNA and copy number alteration showed that our DNA signature has the highest overall AUC (fi gure 6A, B; appendix pp 31, 78).
There is a low alteration rate for most of the genes identifi ed in the signature: 154 (56%) of 276 genes had copy-number alterations in zero to 39 patients (of a total sample size of 397 patients), which is less than 10% of the total combined cohorts size (appendix p 79). p<0·0001, two-sided Mann-Whitney U test). Second, percentage of genome alteration diff ers signifi cantly between the classes predicted by the signature and can be estimated from the gene signature (Spearman's correlation between whole-genome and signatureestimated percentage of genome alteration PGA 0·73; p<0·0001), thereby providing similar prognostic information. Importantly, signature-based estimates of percentage of alteration remain highly prognostic, and the addition of 30 genes (selected from the Toronto cohort) improves estimates of percentage of alteration in the validation cohorts (eg, MSKCC: Spearman's 0·73 vs 0·87; p<0·0001; appendix p 32). The HR of percentage of genome alteration as a continous variable estimated from these 306 genes is identical to that of the true percentage of genome alteration in the MSKCC cohort and nearly identical to that of the Cambridge cohort. Taken together, these results show that our treatment-independent DNA-prognostic signature measures genomic instability in addition to lipid metabolism pathways, suggesting our signature might identify candidates for treatment-intensifi cation trials targetting these processes (appendix pp 86-91).
Discussion
Our fi ndings show that combined indices of genomic instability and hypoxia can improve accuracy of prognosis in patients with localised prostate cancer in the context of present clinicopathological variables. Development of prostate-cancer biomarkers to guide disease management at the time of diagnosis is a diffi cult but crucial challenge in view of the high rates of overtreatment and clinical relapse. 30 Initial investigation in the Toronto cohort showed striking genomic heterogeneity in the pretreatment biopsies from these patients, and has implications for the discovery of driver mutations in prostate cancer. No copy number alterations were recurrent in more than 47% of patients and the number of alterations per patient ranged from zero to 187. We were, however, able to identify independent molecular prognostic subtypes based on genome-wide copy number alteration profi les in the Toronto cohort.
Inclusion of additional patients from the independent MSKCC cohort of low-risk and intermediate-risk patients ) and when applied to the full pooled radical prostatectomy cohort (n=271) the signature for copy number alteration identifi es patients who will fail rapidly (B). HR=hazard ratio. Signature positive=patients whose tumour genomics were positive for the 100-loci DNA. Signature negative=patients whose tumour genomics were negative for the DNA signature. 2·8 (1·4-6·0; 0·0060) 2·9 (1·1-8·2; 0·038) 2·9 (1·0-8·2; 0·050)
Data are hazard ratio (95% CI; p value) or hazard ratio (95% CI). Data are provided for the 100-loci DNA signature in each full validation cohort on the basis of Cox proportional hazard models including only the marker of interest (univariate) and models including relevant clinical covariates as in the multivariate models in table 1 (multivariate). The AUC and C index are provided for the continuous signature risk score. MSKCC=Memorial Sloan Kettering Cancer Center. AUC=area under the receiver operator curve. *Data are based on 18-month biochemical recurrence. Patients fl agged by our copy-number alteration-based signature had biochemical relapse rates that were increased by up to six times, and were at risk of failure within 18 months, all within the clinical context of Gleason score, T category, and PSA. In particular, this signature is highly eff ective for low-risk patients, because it can identify those ineligible for active surveillance and provide additional assurance for those who are. For instance, if the DNA signature was used by clinicians today, of 1000 patients diagnosed with localised disease, 144 patients would be off ered more aggressive treatment (all signature-positive patients) and 650 would have the support for active surveillance instead of local treatment (low-risk to intermediate-risk signature-negative patients).
Preclinical experimental work supports hypoxia generating a mutator phenotype (decreased DNA repair leading to increased mutation rate and genomic instability) and selecting for genetically unstable clones, in addition to an increased capacity for distant metastases. 18 This metastatic phenotype occurs independently of local treatment; hypoxia is associated with both local relapse after image-guided radiotherapy and biochemical failure and distant metastasis in patients receiving image-guided radiotherapy or radical prostatectomy for prostate cancer. 19, 20 Here we have shown that simultaneous measurement of tumour hypoxia and genomic instability can improve the prognostic capability of a pretreatment biopsy by combining the independent biology of cancer genomics with the tumour microenvironment. Moreover, the poor prognosis previously associated with hypoxia 19, 20 might have been related to genomic instability within a subset of these specimens, because hypoxia itself was not associated with poor prognosis in the absence of a heightened percentage of genome alteration.
Cancer-cell metabolism (increased glycolysis, high lactate, and hypoxia) is related to oncogene activation and loss of tumour suppressor genes, and increased lipid and fatty acid synthesis have been associated with progression of prostate cancer. 31, 32 Therefore it is striking that our supervised machine-learning approach led to the discovery of a genetic signature enriched for genes involved in lipid biology. Combined with the fi nding that constitutive activation of mTORC1 renders hypoxic cells dependent on exogenous desaturated lipids, our signature could represent abnormalities in cancer metabolism amenable to targeting of lipid synthesis. [31] [32] [33] [34] Further more, our signature effi ciently captures the prognostic eff ect of percentage of genome alteration-a surrogate for genomic instability. Because androgen deprivation therapy improves oxygenation 35 and reduces DNA repair 36 in patients with prostate cancer, we speculate that such therapies targeting hypoxia and genomic instability might be eff ective in prevention of clinical relapse. Patients fl agged by our signature might benefi t from patient-specifi c intensifi cation with androgen deprivation therapy or other systemic therapies We trained a clinical model (in green) with clinical variables: pretreatment PSA, biopsy-based Gleason score, and T category. We compared our DNA-based signature (CNA_RF, shown in red) with these signatures in the 108 Memorial Sloan Kettering Cancer Center patients with information about both mRNA and CNA. The DNA, RNA, and clinical signatures were trained in a cohort of 293 lowrisk to intermediate-risk patients with prostate cancer (A) and 1299 low-risk to high-risk patients (B), including some with locally advanced disease. In cases where more than one study published more than one signature, only the best performing signature is shown. CNA=copy number alterations. AUC=area under the receiver operator curve. to off set both local and systemic resistance, independent of primary treatment.
To our knowledge, this is the fi rst report of biopsydriven, DNA-based indices that predicts prognosis in patients who received either image-guided radiotherapy or radical prostatectomy as primary therapy for patients with prostate cancer (panel). DNA alterations might be less variable than RNA abundance patterns within intraprostatic biopsies from dynamic tumour microenvironments, and more stable ex vivo during formalinfi xed, paraffi n-embedded protocols. This fi nding suggests that our DNA signatures are robust for clinical application. Because our training cohort was obtained before primary therapy, our study supports the characterisation of complex indices, showing a priori interpatient heterogeneity, soon after diagnostic MRIguided or transurethral ultrasound-guided biopsies. Indeed, we have shown that frozen biopsies are amenable to whole-genome sequencing to assess intrapatient heterogeneity in genomic aberrations (Boutros PC, unpublished).
Our study has several caveats. Use of biochemical relapse as an endpoint is suboptimum compared with prostate cancer-specifi c mortality or time to metastasis. Nonetheless, our signature shows promise in identifi cation of patients with metastasis, and can identify patients who will have biochemical relapse before 18 months, which has been shown to be predictive for prostate cancer-specifi c mortality. 6, 7 Although the cohorts diff er slightly in the distribution of clinicopathological factors, these diff erences changed neither treatment nor survival, making it very unlikely that the diff erences aff ect the interpretation of our results. Nevertheless, we did systematically stratify our analyses according to these factors when we assessed prognostic markers. A subset of patients were given adjuvant treatment; however, we do not yet know how adjuvant treatment aff ects the performance of our signature. We will explore this outcome in new cohorts of patients treated with imageguided radiotherapy or radical prostatectomy with or without androgen deprivation therapy, and assess whether the biomarker would become a predictive, rather than a solely prognostic, biomarker. From a technical perspective, despite diff erent resolutions between the copy number alteration platforms used for each cohort, the copy number alteration indices developed in the Toronto cohort validated in the radical prostatectomy cohorts. The hypoxia probes measure global hypoxia within a prostatecancer locale, but do not measure intracellular hypoxia. As a result, the DNA is obtained from a large region relative to sites of hypoxia. In future studies we will characterise the DNA, RNA, and epigenetic profi les of foci within patients who receive oral pimonidazole before treatment to investigate the genomic-hypoxia prognostic association in fi ner detail. Finally, eff orts are underway to reduce the signature size without loss of prognostic information related to metabolism or genomic instability, and to improve the sensitivity of our signature with multimodal data sets (eg, combined DNA, RNA and epigenetic analyses) emerging from studies from the International Cancer Genome Consortium and The Cancer Genome Atlas.
Identifi cation of the correct patients to treat while avoiding overtreatment in the low-risk to intermediaterisk group remains an important clinical dilemma. We envision the use of genomic instability and microenvironment signatures to divert patients from present clinical risk categories to novel clinical trials of treatment intensifi cation, whereby patients with poor prognosis based on these novel biomarkers can be enrolled into trials that add combined local and systemic therapies. Additionally, low-risk and intermediate-risk patients with low levels of hypoxia and and low percentages of genome alteration could be entered into clinical trials of active surveillance. These precision medicine approaches set the stage for novel treatment intensifi cation and treatment deintensifi cation trials to either increase cure rates by prevention of progression to metastatic castration-resistant prostate cancer or to reduce the burden of overtreatment.
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Panel: Research in context
Systematic review
We reviewed previous studies on the basis of PubMed searches done between Jan 1, 1990, and Dec 31, 2013, with the terms: "genomics", "DNA", "RNA", "hypoxia", "prognosis", "radiotherapy", "surgery", "radical prostatectomy", "aCGH", "RNA expression", "arrays", "classifi er", and "biomarker". We focused on multigene indices that had been validated in at least one cohort, and noted many previously published RNA signatures for prognosis in prostate cancer and for hypoxia in various tissue types. To the best of our knowledge, no multigene DNA signature exists, and no biomarker assesses genomics and the tumour microenvironment simultaneously.
Interpretation
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